Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM Cadrenal Therapeutics acquires VLX-1005 drug for blood clotting disorder
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
Aug 6, 2024 09:00AM
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM
Jun 3, 2024 09:00AM
May 23, 2024 09:00AM
May 9, 2024 09:00AM
Apr 11, 2024 04:30PM Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
Apr 9, 2024 09:05AM
Apr 9, 2024 09:00AM
Mar 11, 2024 09:00AM
Feb 26, 2024 09:00AM
Feb 8, 2024 09:02AM
Feb 8, 2024 09:00AM
Jan 31, 2024 09:00AM Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
Dec 12, 2023 09:03AM
Dec 12, 2023 09:00AM
Nov 20, 2023 06:16AM
Oct 16, 2023 08:38AM
Jul 24, 2023 09:01AM
Jul 24, 2023 09:00AM
May 10, 2023 09:00AM Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update
Mar 30, 2023 09:02AM
Mar 30, 2023 09:00AM
Mar 9, 2023 09:00AM
Feb 8, 2023 09:00AM
Jan 23, 2023 08:31AM
Jan 23, 2023 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All